These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 31868943)

  • 1. A systematic review of the effects of oleoylethanolamide, a high-affinity endogenous ligand of PPAR-α, on the management and prevention of obesity.
    Tutunchi H; Saghafi-Asl M; Ostadrahimi A
    Clin Exp Pharmacol Physiol; 2020 Apr; 47(4):543-552. PubMed ID: 31868943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oleoylethanolamide: The role of a bioactive lipid amide in modulating eating behaviour.
    Sihag J; Jones PJH
    Obes Rev; 2018 Feb; 19(2):178-197. PubMed ID: 29124885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oleic acid-derived oleoylethanolamide: A nutritional science perspective.
    Bowen KJ; Kris-Etherton PM; Shearer GC; West SG; Reddivari L; Jones PJH
    Prog Lipid Res; 2017 Jul; 67():1-15. PubMed ID: 28389247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor alpha (PPAR-alpha).
    Guzmán M; Lo Verme J; Fu J; Oveisi F; Blázquez C; Piomelli D
    J Biol Chem; 2004 Jul; 279(27):27849-54. PubMed ID: 15123613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oleoylethanolamide: A novel pharmaceutical agent in the management of obesity-an updated review.
    Laleh P; Yaser K; Alireza O
    J Cell Physiol; 2019 Jun; 234(6):7893-7902. PubMed ID: 30537148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oleoylethanolamide, an endogenous PPAR-alpha agonist, lowers body weight and hyperlipidemia in obese rats.
    Fu J; Oveisi F; Gaetani S; Lin E; Piomelli D
    Neuropharmacology; 2005 Jun; 48(8):1147-53. PubMed ID: 15910890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oleoylethanolamide supplementation in obese patients newly diagnosed with non-alcoholic fatty liver disease: Effects on metabolic parameters, anthropometric indices, and expression of PPAR-α, UCP1, and UCP2 genes.
    Tutunchi H; Ostadrahimi A; Saghafi-Asl M; Hosseinzadeh-Attar MJ; Shakeri A; Asghari-Jafarabadi M; Roshanravan N; Farrin N; Naemi M; Hasankhani M
    Pharmacol Res; 2020 Jun; 156():104770. PubMed ID: 32217148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of oleoylethanolamide, an endogenous PPAR-α agonist, on risk factors for NAFLD: A systematic review.
    Tutunchi H; Ostadrahimi A; Saghafi-Asl M; Maleki V
    Obes Rev; 2019 Jul; 20(7):1057-1069. PubMed ID: 31111657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of oleoylethanolamide on diet-induced nonalcoholic fatty liver in rats.
    Li L; Li L; Chen L; Lin X; Xu Y; Ren J; Fu J; Qiu Y
    J Pharmacol Sci; 2015 Mar; 127(3):244-50. PubMed ID: 25837920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oleoylethanolamide: A fat ally in the fight against obesity.
    Brown JD; Karimian Azari E; Ayala JE
    Physiol Behav; 2017 Jul; 176():50-58. PubMed ID: 28254531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feeding regulation by oleoylethanolamide synthesized from dietary oleic acid.
    Igarashi M; Iwasa K; Yoshikawa K
    Prostaglandins Leukot Essent Fatty Acids; 2021 Feb; 165():102228. PubMed ID: 33385936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The lipid messenger OEA links dietary fat intake to satiety.
    Schwartz GJ; Fu J; Astarita G; Li X; Gaetani S; Campolongo P; Cuomo V; Piomelli D
    Cell Metab; 2008 Oct; 8(4):281-288. PubMed ID: 18840358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oleoylethanolamide, an endogenous PPAR-α ligand, attenuates liver fibrosis targeting hepatic stellate cells.
    Chen L; Li L; Chen J; Li L; Zheng Z; Ren J; Qiu Y
    Oncotarget; 2015 Dec; 6(40):42530-40. PubMed ID: 26729705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brain molecules and appetite: the case of oleoylethanolamide.
    Sarro-Ramírez A; Sánchez-López D; Tejeda-Padrón A; Frías C; Zaldívar-Rae J; Murillo-Rodríguez E
    Cent Nerv Syst Agents Med Chem; 2013 Mar; 13(1):88-91. PubMed ID: 23464987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological functions and metabolism of oleoylethanolamide.
    Thabuis C; Tissot-Favre D; Bezelgues JB; Martin JC; Cruz-Hernandez C; Dionisi F; Destaillats F
    Lipids; 2008 Oct; 43(10):887-94. PubMed ID: 18704536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of food intake by oleoylethanolamide.
    Lo Verme J; Gaetani S; Fu J; Oveisi F; Burton K; Piomelli D
    Cell Mol Life Sci; 2005 Mar; 62(6):708-16. PubMed ID: 15770421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of oleoylethanolamide on fatty acid uptake in small intestine after food intake and body weight reduction.
    Yang Y; Chen M; Georgeson KE; Harmon CM
    Am J Physiol Regul Integr Comp Physiol; 2007 Jan; 292(1):R235-41. PubMed ID: 16902188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dysfunctional oleoylethanolamide signaling in a mouse model of Prader-Willi syndrome.
    Igarashi M; Narayanaswami V; Kimonis V; Galassetti PM; Oveisi F; Jung KM; Piomelli D
    Pharmacol Res; 2017 Mar; 117():75-81. PubMed ID: 28007570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The satiety factor oleoylethanolamide impacts hepatic lipid and glucose metabolism in goldfish.
    Gómez-Boronat M; Velasco C; Isorna E; De Pedro N; Delgado MJ; Soengas JL
    J Comp Physiol B; 2016 Dec; 186(8):1009-1021. PubMed ID: 27277972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oleoylethanolamide, a natural ligand for PPAR-alpha, inhibits insulin receptor signalling in HTC rat hepatoma cells.
    Martínez de Ubago M; García-Oya I; Pérez-Pérez A; Canfrán-Duque A; Quintana-Portillo R; Rodríguez de Fonseca F; González-Yanes C; Sánchez-Margalet V
    Biochim Biophys Acta; 2009 Aug; 1791(8):740-5. PubMed ID: 19345745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.